This study was designed to evaluate the efficacy of Remdesivir and Baricitinib combination therapy for the treatment of severe Acute Respiratory Distress Syndrome (ARDS) caused by Coronavirus disease 2019 (COVID-19). Our aim is to compare the outcome of the "Remdesivir + Baricitinib" combination against "Remdesivir + Tocilizumab" therapy and find the best option for the management of ARDS in COVID-19 patients.
Drug: Remdesivir
Remdesivir 100 IV Infusion as a lyophilized powder
Other Name: Ninavir
Drug: Baricitinib
Baricitinib oral tablet form
Drug: Tocilizumab
Tocilizumab IV Infusion
Inclusion Criteria:
Severe COVID-19 patients require hospitalization under HDU/ICU. The SARSCoV-2 infection
will be confirmed by RT PCR / CT Chest in every case.
Exclusion Criteria:
Participants with uncontrolled clinical status who were hospitalized from the before.
Contraindication / possible drug interaction. Participants who have any severe and/or
uncontrolled medical conditions like, Severe ischemic heart disease, epilepsy, malignancy,
Pulmonary/ renal/hepatic disease, AIDS, Pulmonary TB, pregnancy, Corpulmonale, and etc.
M. Abdur Rahim Medical College Hospital
Dinajpur, Bangladesh
Investigator: Akter Kamal, MD, PhD
Contact: 0088017233991
kamalaktar@yahoo.com
Abu Taiub Mohammed Mohiuddin Chowdhury, MBBS, MD
008801817711079
dr_mohiuddinchy@yahoo.com
Akter Kamal, MD, PhD
008801817233991
kamalaktar@yahoo.com